A multicenter study evaluating efficacy and safety of the ledipasvir/sofosbuvir (LDV/SOF) for 12 weeks, in chronic genotype 1 and 4 hepatitis C virus infected patients with thalassemia major

Trial Profile

A multicenter study evaluating efficacy and safety of the ledipasvir/sofosbuvir (LDV/SOF) for 12 weeks, in chronic genotype 1 and 4 hepatitis C virus infected patients with thalassemia major

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
    • 01 Aug 2017 Results published in the Alimentary Pharmacology and Therapeutics
    • 01 Aug 2017 Status changed from active, no longer recruiting to completed according to results published in the Alimentary Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top